Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) priced a public offering of senior unsecured notes totaling €5.0 billion across five tranches with maturities from 2030 to 2055 and coupons ranging from 2.973% to 4.581%. The notes will be issued by BMS Ireland Capital Funding DAC and fully guaranteed on a senior unsecured basis by Bristol-Myers Squibb Company.
The company expects closing on November 10, 2025, subject to customary conditions. Net proceeds, together with approximately $3.0 billion of cash on hand, are intended to fund a tender offer and other repurchases/repayments, pay fees and expenses, and, if any remains, for general corporate purposes.
Bristol Myers Squibb (NYSE: BMY) will present new long‑term and real‑world cardiovascular data at the American Heart Association Scientific Sessions 2025 (Nov 7–10, 2025).
Key highlights include nearly four years of EXPLORER‑LTE long‑term extension data for Camzyos (mavacamten), ~34 months of REMS real‑world safety data, and analyses of hospital/ER rates, monotherapy effectiveness across global cohorts, and ODYSSEY‑HCM results.
Camzyos is approved in more than 50 countries and prescribed in the U.S. by >4,000 clinicians to >20,000 patients; safety details include LVEF changes and specific adverse event rates reported in trials.
Bristol Myers Squibb (NYSE: BMY) commenced cash tender offers on November 3, 2025 to purchase specified outstanding notes in two pools: Pool 1 (up to $4,000,000,000 aggregate purchase price) and Pool 2 (up to $3,000,000,000 aggregate purchase price).
Key mechanics: Early Tender Deadline is November 17, 2025; Price Determination Date is November 18, 2025; Expiration Date is December 3, 2025. Early tender premium is $50 per $1,000 and Total Consideration includes fixed spreads to specified U.S. Treasury yields. Offers are conditioned on a Finance Sub new notes offering plus approximately $3.0 billion of BMS cash to fund purchases.
Bristol Myers Squibb (NYSE: BMY) reported third quarter 2025 financial results and will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET on October 30, 2025. Detailed Q3 2025 earnings press release and investor presentation are available on the company’s Investor Relations website.
A replay of the webcast will be available on the Investor Relations site approximately three hours after the conference call concludes. Media and investor contact emails are provided for follow-up information.
Bristol Myers Squibb (NYSE:BMY) reported Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial showing sustained efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.
Key results: ACR20 at Week 16 was 54.2% (placebo 34.1%, p<0.0001) and was maintained at Week 52 at 63.1%; patients switched from placebo reached 60.8% at Week 52. Radiographic no-progression rates: 82.0% (Sotyktu) vs 71.5% (placebo) at Week 16; sustained through Week 52. Integrated Phase 2 PAISLEY-SLE/LTE data showed durable efficacy and consistent safety with up to 4 years exposure. Regulatory reviews are ongoing; FDA PDUFA goal date: March 6, 2026.
Bristol Myers Squibb (NYSE: BMY) presented updated Phase 1 Breakfree-1 data (Oct 25, 2025) for autologous CD19 NEX-T CAR T therapy BMS-986353 in systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathies (IIM).
Across 71 treated patients, results show robust CAR T expansion, complete B cell depletion and a potential immune reset; 94% of evaluable patients remained off chronic immunosuppressive therapy at analysis. Key cohort results: SSc pFVC median +10% at six months (ILD subgroup); SLE: 92% off SLE-specific ISTs and DL1 selected as RP2D; IIM: 91% achieved moderate-major responses. Safety: mostly transient, early TEAEs with some grade 3 ICANS/CRS events that resolved.
SystImmune and Bristol Myers Squibb (NYSE: BMY) presented first global Phase I results for iza-bren (EGFR x HER3 bispecific ADC) at ESMO 2025 on Oct 17, 2025.
At data cut-off July 23, 2025, 107 heavily pre-treated patients were treated. At 2.5 mg/kg (Days 1 & 8 q3w), confirmed response rate was 55% (11/20) with median progression-free survival 5.4 months. Confirmed responses occurred in EGFR-mutated (3/10) and EGFR wild-type (3/4) NSCLC subgroups. No interstitial lung disease observed; hematologic AEs (neutropenia) were manageable and prompted mandatory preventative measures in ongoing studies. Breakthrough Therapy designation granted Aug 2025.
insitro and Bristol Myers Squibb (NYSE: BMY) extended their collaboration on October 14, 2025 to apply insitro’s ChemML™ platform toward discovery of small-molecule therapies for a novel preclinical ALS target identified in the prior biological evaluation phase.
The one-year extension may provide up to $20 million in new funding and the partnership could deliver a program with aggregate milestone and royalty value exceeding $2 billion. ChemML™ capabilities cited include large-scale QAL data generation, ADMET modeling, an AI-driven design loop, and a 192 H100 GPU compute cluster.
Bristol Myers Squibb (NYSE: BMY) will present oncology data at ESMO Congress 2025 in Berlin, Oct 17–21, showcasing results from >50 company‑sponsored, investigator‑sponsored and collaborative studies across >10 cancer types.
Key highlights include first disclosure of a global Phase 1 study of iza‑bren (BL‑B01D1) (EGFR×HER3 ADC) and data that supported an FDA Breakthrough Therapy designation; late‑breaking PFS and first OS from CheckMate‑8HW in MSI‑H/dMMR mCRC; five‑year DFS/OS/ctDNA follow‑up from CheckMate‑274 in high‑risk MIUC; and the nine‑year final analysis of CheckMate‑238 in resected advanced melanoma.
SystImmune (collaborating with BMY) announced the first patient treated in the IZABRIGHT-Breast01 Phase 2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs.
That event triggered a $250 million one-time milestone payment from Bristol Myers Squibb (BMY) under the 2023 collaboration and exclusive license agreement. SystImmune is eligible for up to an additional $250 million near-term and up to $7.1 billion in further contingent development, regulatory and sales milestones. Iza-bren has received Breakthrough Therapy Designation from the FDA for previously treated advanced EGFR-mutated NSCLC and is being evaluated in multiple ongoing global trials.